Multicenter, Prospective, Comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications

Clinical Interventions in Aging

Volumn 10, Issue , 2014, Pages 277-286

  Zhang, Li Tao ^a   Lee, Sung Won ^b   Park, Kwangsung ^c   Chung, Woo Sik ^d   Kim, Sae Woong ^e   Hyun, Jae Seog ^f   Moon, Doo Geon ^g   Yang, Sang Kuk ^h   Ryu, Ji Kan ⁱ   Yang, Dae Yul ^j   Moon, Ki Hak ^k   Min, Kweon Sik ^l   Park, Jong Kwan ^a  

^a Chonbuk National University Medical School and Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Gyeongsang National University   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Konkuk University   (South Korea)

ⁱ Inha University School of Medicine   (South Korea)

^j Hallym University   (South Korea)

^k Yeungnam University College of Medicine   (South Korea)

^l Inje University   (South Korea)

more..

Author keywords

Alfuzosin; Antihypertensive medication; Benign prostatic hyperplasia; Blood pressure; Lower urinary tract symptoms

Indexed keywords

ALFUZOSIN; ANTIHYPERTENSIVE AGENT; QUINAZOLINE DERIVATIVE; URINARY TRACT AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FLOW RATE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL DYSFUNCTION; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; LOWER URINARY TRACT SYMPTOMS; PROSTATIC HYPERPLASIA;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; UROLOGICAL AGENTS;

EID: 84921514576     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S74102     Document Type: Article

References (26)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-471.
3. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185:1793-1803.
4. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46:547-554.
5. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006;175:35-42.
6. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years - characterization of patients and ultimate outcomes. Eur Urol. 2000;37:528-536.
7. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223.
8. Mondaini N, Giubilei G, Ungar A, et al. Alfuzosin (10mg) does not affect blood pressure in young healthy men. Eur Urol. 2006;50:1292-1298.
9. Kaplan SA. Uroselective alpha-blockade for benign prostatic hyperplasia: Clinically significant or marketing savvy? Urology. 1999; 54:776-779.
10. Chau LH, Tai DC, Fung BT, Li JC, Fan CW, Li MK. Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: A prospective randomized controlled trial. Int J Urol. 2011; 18:510-514.
11. Ahmed AF, Al-Sayed AY. Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: Prospective, randomized, comparative study. Korean J Urol. 2010;51:193-197.
12. Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: A prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003;62:425-429.
13. Basar MM, Atan A, Ozergin O, Yildiz M. The efficacy of alfuzosin treatment in patients with prostatism. Int Urol Nephrol. 2001;33: 493-497.
14. Rowe E, Smith C, Laverick L, Elkabir J, Witherow RO, Patel A. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. J Urol. 2005;173:2044-2047.
15. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390-1393.
16. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendation. J Urol. 2003;170(2 Pt 1):530-547.
17. Song K, Choo MS, Lee KS, et al. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: Evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. Urology. 2011;77:1177-1182.
18. Vallancien G, Emberton M, Alcaraz A, et al; ALF-ONE Study Group. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice. BJU Int. 2008;101: 847-852.
19. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study. BJU Int. 2006;97: 734-741.
20. Nickel JC, Elhilali M, Emberton M, Vallancien G; Alf-One Study Group. The beneficial effect of alfuzosin 10 mg once daily in ‘real-life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int. 2006;97:1242-1246.
21. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005;95:1006-1012.
22. Mottet N, Bressolle F, Delmas V, Robert M, Costa P. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol. 2003;44:101-105.
23. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: A 2-year experience in ‘real-life’ practice. BJU Int. 2006;97:513-519.
24. Roehrborn C, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92: 257-261.
25. van Kerrebroeck P, Jardin A, van Cangh P, Laval KU; ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study. Eur Urol. 2002;41: 54-60.
26. Lee SH, Park KK, Mah SY, et al. Effects of alpha-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer Prostatic Dis. 2010;13: 333-337.